Amends Federal patent law to extend the patent term for certain drugs composed of non-steroidal anti-inflammatory agents if during the regulatory review process the patentee: (1) filed a new drug application in 1982; (2) awaited approval by the Food and Drug Administration for at least 78 months; and (3) such new drug application was approved in 1991. Prescribes a formula for patent term extension and sets forth administrative notification procedures.
Introduced in House
Introduced in House
Referred to the House Committee on Judiciary.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line